Table 1.

Baseline characteristics of all SSc patients in the study population who were positive for anti–topoisomerase I IgG^*

	All patients (n = 103)
Demographic characteristics
Female sex	70 (68)
Age, mean ± SD years	53.0 ± 14.8
Smoking (ever)	50 (49)
Disease duration
Since onset of first Raynaud’s symptom, median (IQR) years	5.8 (2.1–13.4)
Since onset of first non‐Raynaud’s symptom, median (IQR) years	2.8 (0.8–9.3)
Organ involvement
Diffuse cutaneous SSc	49 (48)
Modified Rodnan skin thickness score, median (IQR)	6 (2–12)
FVC%, mean ± SD	87 ± 27
DLco%, mean ± SD	63 ± 17
History of renal crisis	3 (3)
Digital ulcers	14 (14)
Pulmonary hypertension	5 (5)
History of immunosuppressive treatment†
HSCT	7 (7)
CYC (ever)	24 (23)
MMF (ever)	1 (1)

^*Except where indicated otherwise, values are the number (%) of patients. SSc = systemic sclerosis; IQR = interquartile range; FVC% = forced vital capacity % predicted; DLco% = diffusing capacity for carbon monoxide % predicted.

^†Immunosuppressive treatment includes the use of hematopoietic stem cell transplantation (HSCT), cyclophosphamide (CYC), or mycophenolate mofetil (MMF).